IDEAYA Biosciences Inc. Stock News

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics based on Synthetic Lethality, announced the a

Wall Street analysts expect IDEAYA Biosciences (NASDAQ:IDYA) to post earnings of $1.00 per share for the current quarter, Zacks reports. Two analysts have made estimates for IDEAYA Biosciences’ earn

If you've got the stomach for volatility, the potential oncology breakthroughs underlining IDYA stock makes for a very interesting pick.

Both companies boosted price and number of shares in their offerings Continue reading...

Here's what pushed up shares of the highest-flying healthcare stocks.

The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on

The

The development-stage drug developer is selling common stock to raise cash. It's a wise move.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share, before un

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) Adverum Biotechnologies Inc...

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch Health

Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) ADC Therapeutics SA (NYSE:...